•
Sep 30, 2021

Beauty Health Q3 2021 Earnings Report

Reported record results driven by strength in the U.S. and EMEA and significant growth in APAC.

Key Takeaways

The Beauty Health Company reported a strong third quarter with net sales of $68.1 million, a 97% increase compared to Q3 2020. The company raised its full-year guidance for net sales to $245 million to $255 million and adjusted EBITDA to $30 million.

Net sales increased 97% compared to Q3 2020, reaching $68.1 million.

Delivery Systems net sales increased to $36.2 million, compared to $15.9 million in Q3 2020.

Consumables net sales increased to $32.0 million, compared to $18.6 million in Q3 2020.

Gross margin increased to 67.6% compared to 60.6% in Q3 2020.

Total Revenue
$68.1M
Previous year: $34.6M
+97.2%
EPS
-$1.63
Previous year: -$0.06
+2616.7%
Gross Margin
67.6%
Previous year: 60.6%
+11.6%
Adjusted EBITDA
$5.8M
Previous year: $7.6M
-23.7%
Adjusted EBITDA Margin
8.5%
Previous year: 21.9%
-61.2%
Gross Profit
$46.1M
Previous year: $23M
+100.1%
Cash and Equivalents
$719M
Previous year: $25K
+2874300.0%
Free Cash Flow
$148K
Previous year: -$1.66M
-108.9%
Total Assets
$998M
Previous year: $438K
+227928.9%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

BeautyHealth raised its outlook to reflect the acceleration of performance in BeautyHealth's third quarter, momentum in health and wellness, as well as confidence in its business as it executes against its growth plan.

Positive Outlook

  • Net sales of $245 million to $255 million, compared to the prior guidance of $230 million to $240 million.
  • Adjusted EBITDA of approximately $30 million, compared to the prior guidance of approximately $25 million.

Challenges Ahead

  • Achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in the Company’s filings with the Securities and Exchange Commission.
  • The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account any unannounced acquisitions, dispositions or financings during 2021.
  • The Company remains cautious of the potential risk for further market closures or other restrictive measures from new COVID-19 strains and the uneven global rollout and adoption of vaccines, as well as inflationary headwinds related to higher raw material, shipping and labor costs.
  • BeautyHealth’s outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.

Revenue & Expenses

Visualization of income flow from segment revenue to net income